Angiogenesis inhibition and preeclampsia

Journal of Hypertension

Volumn 27, Issue 4, 2009, Pages 707-708

  Jankowski, Marek ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLCHOLINE; BASIC FIBROBLAST GROWTH FACTOR; BRADYKININ; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GUANYLATE CYCLASE INHIBITOR; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SURAMIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; NOTE; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; VASCULAR RESISTANCE;

EID: 67649669813     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283293dc5     Document Type: Note

References (13)

1. Podjarny E, Baylis C, Losonczy G. Animal models of preeclampsia. Semin Perinatol 1999; 23:2-13.
2. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38:718-722.
3. LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008; 51:982-988.
4. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46:1243-1249.
5. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46:1077-1085.
6. Dechend R, Luft FC. Angiogenesis factors and preeclampsia. Nat Med 2008; 14:1187-1188.
7. Carlström M, Wentzel P, Skøtt O, Persson AEG, Eriksson UJ. Angiogenesis inhibition causes hypertension and placental dysfunction in a rat model of preeclampsia. J Hypertens 2009; 27:829-837.
8. Mauriz JL, Gonzá lez-Gallego J. Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. J Pharm Sci 2008; 97:4129-4154.
9. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672-683.
11. Solomon CG, Seely EW. Preeclampsia: searching for the cause. N Engl J Med 2004; 350:641-642.
12. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-371.
13. Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat preeclampsia model. Eur J Pharmacol 2008; 589:180-187.